Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

Dominantly Inherited Alzheimer Network (DIAN)

Start: January 2009
End: July 2024
Enrollment: 700

What Is This Study About?

This study will identify the biological changes that occur in the development of Alzheimer's disease to improve early diagnosis and to track progression of the disease. Researchers will collect biological information from adults who have parents a known inheritable, genetic mutation for Alzheimer's disease, specifically mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein (APP) genes. Participants will undergo genetic testing, brain imaging, and provide blood and spinal fluid samples. Researchers will measure the amount of abnormal amyloid in the brain and spinal fluid, changes in brain size (e.g. shrinkage), and brain metabolism (energy processing). They will compare the changes that occur in participants with and without mild Alzheimer's symptoms, who may or may not have an Alzheimer's genetic mutation. All results will be stored in the Dominantly Inherited Alzheimer's Network (DIAN) Central Archive, an international database that allows qualified researchers to access and analyze the information. All information will be anonymized to ensure the privacy of the participants. Participants may choose to receive the results of their genetic test, and if so, will have access to genetic counseling at no cost.

Do I Qualify To Participate in This Study?

Minimum Age: 18 Years

Maximum Age: N/A

Must have:

  • Child who is 18 years old or older of an individual with a known mutation for autosomal dominant Alzheimer's disease
  • Cognitively normal; may allow enrollment of participants with very mild, mild, or moderate cognitive impairment
  • Fluent at the 6th grade level in a language approved by investigators
  • Has two people who are not siblings who can serve as sources for the study

Must NOT have:

  • Medical or psychiatric illness that would interfere with completing initial and follow-up visits
  • Requires nursing home level care

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Study Contact
Alisha Daniels, MD,MHA
DIAN Obs Admin Core

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Mayo Clinic Jacksonville
Jacksonville, FL 32224
Mary Imhansiemhonehi, MPH
Indiana University-Indiana Alzheimer Disease Center
Indianapolis, IN 46202
Jill Buck, RN
Brigham and Women's Hospital
Boston, MA 02115
Colleen Fitzpatrick, MS
Washington University in St. Louis School of Medicine
Saint Louis, MO 63108
Wendy Sigurdson, RN, MPH
New York
Columbia University
New York, NY 10032
Naara Ramirez-Estevez
University of Pittsburgh
Pittsburgh, PA 15260
Zana Ikonomovic, MD
Rhode Island
Butler Hospital
Providence, RI 02906
Courtney Bodge, PhD

Who Sponsors This Study?

Lead: Washington University School of Medicine

Collaborator Sponsor

  • National Institute on Aging (NIA)

Source: ID: NCT00869817

An official website of the U.S. government, managed by the National Institutes on Aging at the National Institutes of Health